Gedatolisib

Also known as: PF-05212384, PKI-587, PF 05212384, PKI 587, PKI587, 1-(4-[4-(dimethylamino)piperidine-1-carbonyl]phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea, N-[4-[[4-(Dimethylamino)-1-piperidinyl]carbonyl]phenyl]-N'-[4-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]phenyl]urea, cc-54, S2628_Selleck

Gedatolisib (CAS 1197160-78-3) is a compound in the Pharma Intermediates category listed in the Jingsj chemical database. It has the molecular formula C32H41N9O4 and a molecular weight of 615.726 g/mol. Key property: a density of 1.4±0.1 g/cm3. No supplier offers are currently listed; request a quote. Record last updated Aug 21, 2026.

CAS No.: 1197160-78-3
Jingsj CID: J-1959382-9
Molecular Formula: C₃₂H₄₁N₉O₄
Molecular Weight: 615.726 g/mol
Category: Pharma Intermediates
Last updated: 8/21/2026

Request MSDS / TDS

No offers for this compound yet.

Request a quote

Physicochemical Properties

Density	1.4±0.1 g/cm3
Exact Mass	615.328125
PSA	128.29000
LogP	-0.76
Refractive Index	1.670
Storage Conditions	2~8°C

Activity & Biological Data

Target	PI3Kα:0.4 nM (IC50) PI3Kβ:6 nM (IC50) PI3Kδ:6 nM (IC50) PI3Kγ:5.4 nM (IC50) PI3Kα-H1047R:0.6 nM (IC50) PI3Kα-E545K:0.6 nM (IC50) mTOR:1.6 nM (IC50) mTORC1 mTORC2
Additional Information	[1]. Venkatesan AM, et al. Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor. J Med Chem. 2010, 53(6), 2636-2645. [2]. Liu T, et al. Dual PI3K/mTOR inhibitors, GSK2126458 and PKI-587, suppress tumor progression and increase radiosensitivity in nasopharyngeal carcinoma. Mol Cancer Ther. 2015 Feb;14(2):429-39. [3]. Freitag H, et al. Inhibition of mTOR's Catalytic Site by PKI-587 Is a Promising Therapeutic Option for Gastroenteropancreatic Neuroendocrine Tumor Disease. Neuroendocrinology. 2017;105(1):90-104.

Target

PI3Kα:0.4 nM (IC50) PI3Kβ:6 nM (IC50) PI3Kδ:6 nM (IC50) PI3Kγ:5.4 nM (IC50) PI3Kα-H1047R:0.6 nM (IC50) PI3Kα-E545K:0.6 nM (IC50) mTOR:1.6 nM (IC50) mTORC1 mTORC2

Additional Information

[1]. Venkatesan AM, et al. Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor. J Med Chem. 2010, 53(6), 2636-2645. [2]. Liu T, et al. Dual PI3K/mTOR inhibitors, GSK2126458 and PKI-587, suppress tumor progression and increase radiosensitivity in nasopharyngeal carcinoma. Mol Cancer Ther. 2015 Feb;14(2):429-39. [3]. Freitag H, et al. Inhibition of mTOR's Catalytic Site by PKI-587 Is a Promising Therapeutic Option for Gastroenteropancreatic Neuroendocrine Tumor Disease. Neuroendocrinology. 2017;105(1):90-104.

Frequently Asked Questions

What is the CAS number of Gedatolisib?

The CAS number of Gedatolisib is 1197160-78-3.

What are the molecular formula and molecular weight of Gedatolisib?

Gedatolisib has molecular formula C32H41N9O4 and molecular weight 615.726 g/mol.

What are the upstream and downstream products of Gedatolisib?

For Gedatolisib, Upstream Products: N,N-Dimethylpiperidin-4-amine.

Data compiled from public chemical databases such as PubChem and supplier catalogs; supplier offers are provided by suppliers.

Last updated: 8/21/2026

How to cite: Jingsj. "Gedatolisib (CAS 1197160-78-3)". Jingsj Chemical Database. https://www.jingsj.com/compound/J-1959382-9 (accessed 2026-11-09).

Data for reference only; verify product details with suppliers before purchase.